Medical - Pharmaceuticals stocks
Every US Medical - Pharmaceuticals company with filed annual reports: 14, in the Healthcare sector, with the ratios the screener prints. A name opens the company’s page, where every filed figure carries the filing it was read from and every price the day of its close.
Medians across Medical - Pharmaceuticals companies
- Price to earnings
- 4.98x of 2
- Price to book
- 0.94x of 9
- Free cash flow yield
- 4.3% of 7
- Return on invested capital, after tax
- -155.2% of 2
- Debt to equity
- 0.26 of 4
- Dividend yield
- 0.1% of 1
The companies
| Company | Market cap | P/E | P/B | EV/EBIT | FCF yld | ROIC | D/E | Div yld |
|---|---|---|---|---|---|---|---|---|
| BeOne Medicines Ltd. ONC | 39.97B | n/a | n/a | n/a | n/a | 33.6% | 0.25 | n/a |
| Galecto, Inc. DMRA | 1.16B | n/a | 4.81x | n/a | n/a | n/a | n/a | n/a |
| Cullinan Therapeutics, Inc. CGEM | 860.4M | n/m | 2.11x | n/a | -20.4% | n/a | n/a | n/a |
| High Tide Inc. HITI | 228.2M | n/m | 3.70x | n/a | 4.3% | n/a | n/a | n/a |
| LifeMD, Inc. LFMD | 118.7M | 9.84x | 4.79x | n/a | 5.8% | n/m | 0.27 | n/a |
| Stablecoin Development Corp. SDEV | 52.8M | n/m | n/m | n/a | n/a | n/m | n/m | n/a |
| 111, Inc. YI | 27.1M | n/m | n/m | n/a | 63.1% | n/m | n/m | n/a |
| PetMed Express, Inc. PETS | 26.4M | n/m | 0.88x | n/a | -129.3% | n/a | n/a | 0.1% |
| Kyntra Bio, Inc. KYNB | 21.7M | 0.12x | n/m | n/a | -22.2% | n/a | n/m | n/a |
| Neuphoria Therapeutics Inc. NEUP | 17.9M | n/m | 0.59x | n/a | n/a | -343.9% | n/a | n/a |
| Rein Therapeutics Inc. RNTX | 17.6M | n/m | 0.94x | n/a | n/a | n/a | n/a | n/a |
| POMDOCTOR Ltd POM | 5.0M | n/m | n/m | n/a | n/m | n/m | n/m | n/a |
| Cellyan Biotechnology Co., Ltd HKPD | 4.6M | n/m | 0.93x | n/a | 10.8% | n/a | 0.48 | n/a |
| Bio Green Med Solution, Inc. BGMS | 4.6M | n/m | 0.67x | n/a | n/a | n/a | 0.0003 | n/a |
Largest published market value first. No ratio orders this list, and a company whose market value is not published is listed last.
Prices as of 2026-10-15. Ratios recomputed from the filings 2026-10-15. Every ratio passes the same applicability gate as the screener and the research page, with the latest filed fiscal year's statements. A list is not a recommendation: see the limits of what this tool can tell you.